BRAF and colorectal cancer: The combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CET) (“triplet regimen”) was approved in November 2020 in Japan as a second-line treatment for BRAF V600E mutation-positive colorectal cancer.